The critical role of the JAK/STAT signaling pathway in advancing cancer immunotherapy was also highlighted in a study by Huang and Zappasodi [58], which showed that JAK1/2 inhibition could enhance PD-1 blockade in mouse models of melanoma by reducing tumor-induced immunosuppression. This evidence concerns the gene SOAT1 and neoplasm.